The Effects of Probiotic Honey Consumption on Metabolic Status in Patients with Diabetic Nephropathy: a Randomized, Double-Blind, Controlled Trial
To the best of our knowledge, this study is the first evaluating the effects of probiotic honey intake on glycemic control, lipid profiles, biomarkers of inflammation, and oxidative stress in patients with diabetic nephropathy (DN). This investigation was conducted to evaluate the effects of probiotic honey intake on metabolic status in patients with DN. This randomized, double-blind, controlled clinical trial was performed among 60 patients with DN. Patients were randomly allocated into two groups to receive either 25 g/day probiotic honey containing a viable and heat-resistant probiotic Bacillus coagulans T11 (IBRC-M10791) (108 CFU/g) or 25 g/day control honey (n = 30 each group) for 12 weeks. Fasting blood samples were taken at baseline and 12 weeks after supplementation to quantify glycemic status, lipid concentrations, biomarkers of inflammation, and oxidative stress. After 12 weeks of intervention, patients who received probiotic honey compared with the control honey had significantly decreased serum insulin levels (− 1.2 ± 1.8 vs. − 0.1 ± 1.3 μIU/mL, P = 0.004) and homeostasis model of assessment-estimated insulin resistance (− 0.5 ± 0.6 vs. 0.003 ± 0.4, P = 0.002) and significantly improved quantitative insulin sensitivity check index (+ 0.005 ± 0.009 vs. − 0.0007 ± 0.005, P = 0.004). Additionally, compared with the control honey, probiotic honey intake has resulted in a significant reduction in total-/HDL-cholesterol (− 0.2 ± 0.5 vs. + 0.1 ± 0.1, P = 0.04). Probiotic honey intake significantly reduced serum high-sensitivity C-reactive protein (hs-CRP) (− 1.9 ± 2.4 vs. − 0.2 ± 2.7 mg/L, P = 0.01) and plasma malondialdehyde (MDA) levels (− 0.1 ± 0.6 vs. + 0.6 ± 1.0 μmol/L, P = 0.002) compared with the control honey. Probiotic honey intake had no significant effects on other metabolic profiles compared with the control honey. Overall, findings from the current study demonstrated that probiotic honey consumption for 12 weeks among DN patients had beneficial effects on insulin metabolism, total-/HDL-cholesterol, serum hs-CRP, and plasma MDA levels, but did not affect other metabolic profiles. http://www.irct.ir: IRCT201705035623N115.
KeywordsProbiotic Honey Supplementation Diabetic nephropathy Metabolic status
The present study was supported by a grant from the Vice-chancellor for Research, KAUMS, and Iran. Special thanks to Gaz Sekkeh Company for providing probiotic and control honey.
NM-A and ZA contributed in conception, data collection, and manuscript drafting. ZE-D, HT, RS-C, and AS contributed in conception, data collection, and manuscript drafting. All authors read and approved the final version of the paper.
Compliance with Ethical Standards
This investigation was conducted in accordance with the Declaration of Helsinki. The informed written consent was taken from all enrolled patients, with ethical clearance for the study obtained from the ethics committee of Kashan University of Medical Sciences (KAUMS).
Conflicts of Interest
The authors declare that they have no conflict of interest.
- 2.Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME (2014) Diabetic kidney disease: a report from an ADA consensus conference. Am J Kidney Dis 64:510–533. https://doi.org/10.1053/j.ajkd.2014.08.001 CrossRefPubMedGoogle Scholar
- 4.McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D (2014) Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan diabetic nephropathy trial. Am J Kidney Dis 64:714–722. https://doi.org/10.1053/j.ajkd.2014.06.008 CrossRefPubMedGoogle Scholar
- 5.Mendez MM, Folgado J, Tormo C, Artero A, Ascaso M, Martinez-Hervás S, Chaves FJ, Ascaso JF, Real JT (2015) Altered glutathione system is associated with the presence of distal symmetric peripheral polyneuropathy in type 2 diabetic subjects. J Diabetes Complicat 29:923–927. https://doi.org/10.1016/j.jdiacomp.2015.05.023 CrossRefPubMedGoogle Scholar
- 6.Herder C, Lankisch M, Ziegler D, Rathmann W, Koenig W, Illig T, Döring A, Thorand B, Holle R, Giani G, Martin S, Meisinger C (2009) Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA survey F3 (Augsburg, Germany). Diabetes Care 32:680–682. https://doi.org/10.2337/dc08-2011 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Hung AT, Lin S-Y, Yang T-Y, Chou C-K, Liu H-C, Lu J-J, Wang B, Chen S-Y, Lien T-F (2012) Effects of Bacillus coagulans ATCC 7050 on growth performance, intestinal morphology, and microflora composition in broiler chickens. Anim Prod Sci 52:874–879. https://doi.org/10.1071/AN11332 CrossRefGoogle Scholar
- 12.Kazzi F, Daher N, Zimmerman G, Garcia M, Schmidt N, Scharf K (2018) Effect of Bacillius coagulans and galactomannans on obese patients undergoing sleeve gastrectomy, a randomized-controlled clinical trial. Altern Ther health med Jun 6. Pii: AT5989. In: Epub ahead of printGoogle Scholar
- 15.Soleimani A, Zarrati Mojarrad M, Bahmani F, Taghizadeh M, Ramezani M, Tajabadi-Ebrahimi M, Jafari P, Esmaillzadeh A, Asemi Z (2017) Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney Int 91:435–442. https://doi.org/10.1016/j.kint.2016.09.040 CrossRefPubMedGoogle Scholar
- 20.Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT (2013) Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 36:845–853. https://doi.org/10.2337/dc12-0840 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Beutler E, Gelbart T (1985) Plasma glutathione in health and in patients with malignant disease. J Lab Clin Med 105:581–584Google Scholar
- 30.McFarlin BK, Henning AL, Bowman EM, Gary MA, Carbajal KM (2017) Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers. World J Gastrointest Pathophysiol 8:117–126. https://doi.org/10.4291/wjgp.v8.i3.117 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Bansal D, Gudala K, Esam HP, Nayakallu R, Vyamusani RV, Bhansali A (2014) Microvascular complications and their associated risk factors in newly diagnosed type 2 diabetes mellitus patients. Int J Chronic Dis 2014:201423–201427. https://doi.org/10.1155/2014/201423 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Alipour B, Homayouni-Rad A, Vaghef-Mehrabany E, Sharif SK, Vaghef-Mehrabany L, Asghari-Jafarabadi M, Nakhjavani MR, Mohtadi-Nia J (2014) Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial. Int J Rheum Dis 17:519–527. https://doi.org/10.1111/1756-185X.12333 CrossRefPubMedGoogle Scholar
- 41.Jager R, Shields KA, Lowery RP, De Souza EO, Partl JM, Hollmer C, Purpura M, Wilson JM (2016) Probiotic Bacillus coagulans GBI-30, 6086 reduces exercise-induced muscle damage and increases recovery. PeerJ 4:e2276. https://doi.org/10.7717/peerj.2276 eCollection 2016CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Bao L, Li J, Zha D, Zhang L, Gao P, Yao T, Wu X (2018) Chlorogenic acid prevents diabetic nephropathy by inhibiting oxidative stress and inflammation through modulation of the Nrf2/HO-1 and NF-kB pathways. Int Immunopharmacol 54:245–253. https://doi.org/10.1016/j.intimp.2017.11.021 CrossRefPubMedGoogle Scholar